reports
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Shar...
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement (“ASR”) with Jefferies LLC (“Jefferies”) to repurchase $100 million of Soleno’s common stock. “These actions demonstrate our confidence in our commer...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
35G GENPACT LIMITED
EXPE EXPEDIA GROUP INC.
CRK COMSTOCK RESOURCES INC.
AXTI AXT INC.
ALB ALBEMARLE CORPORATION
ACRE ARES COMMERCIAL REAL ESTATE
AGO ASSURED GUARANTY LTD.
HRTG HERITAGE INSURANCE HOLDINGS INC.
DRH DIAMONDROCK HOSPITALITY COMPANY
ELY CALLAWAY GOLF COMPANY
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
TALO TALOS ENERGY INC.
LASR NLIGHT
GLOB GAZIT-GLOBE LTD.
ARVN ARVINAS HOLDING
PLMR PALOMAR HOLDINGS
BW BABCOCK & WILCOX ENTERPRISES
TXG 10X GENOMICS INC CLASS A
PGNY PROGYNY
AMPY AMPLIFY ENERGY
EOSE EOS ENERGY ENTERPRISES INC (A)
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
DOCN DIGITALOCEAN HLDGS INC
DSGN DESIGN THERAPEUTICS INC
FIGS FIGS INC
YOU ONTO INNOVATION INC.
PPTA CLEAR SECURE INC
AMPX PERPETUA RESOURCES CORP
OS AMPRIUS TECHNOLOGIES INC
SNDK ONESTREAM INC
CSIOX SANDISK CORP
BALY CATALYST PERINI STRATEGIC INCOM ORD
HOII BALLY'S CORPORATION
REX HOOD GROWTH & INCOME ETF
Oxbridge Highlights 2025/26 Contract Performance Updates and Reports Q...
Oxbridge Highlights 2025/26 Contract Performance Updates and Reports Q3 2025 Results GRAND CAYMAN, Cayman Islands, Nov. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today reported its results for the three and nine months ended September 30, 2025. SurancePlus 2025–2026 Tokenized Reinsurance Update continues to demonstrate strong performance across its 2025–2026 tokenized reinsurance offerings. The Balanced Yield Token (EtaCat Re), which targeted a 20% annual...
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-8...
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) Ongoing Cash and Securities of $206.0 Million as of Third Quarter 2025 Support Continued Pipeline Advancement CARLSBAD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Design Thera...
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and P...
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 2025 and provided an update on the U.S. launch of VYKATTM XR. Third Quarter 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three months ended September 30, 2025 wa...
Oxbridge / SurancePlus Provide Performance Update on 2025/26 Tokenized...
Oxbridge / SurancePlus Provide Performance Update on 2025/26 Tokenized Reinsurance Offerings GRAND CAYMAN, Cayman Islands, Nov. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced an update on the performance of its 2025/2026 tokenized reinsurance securities. – Balanced Yield Token: Targeted 20% - Tracking 25% – High Yield Token: Targeted 42% - Is on track to achieve its targeted return , CEO of , commented, “These results underscore the Company’s c...
Oxbridge / SurancePlus to Speak at Uncorrelated Cayman 2025
Oxbridge / SurancePlus to Speak at Uncorrelated Cayman 2025 GRAND CAYMAN, Cayman Islands, Oct. 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced that Chairman and CEO will speak on the panel “Tokenization and Stablecoins: Building the Bridge Between Traditional Finance and On-Chain Markets” at Uncorrelated Cayman 2025, taking place November 9-11, 2025 at Hotel Indigo Grand Cayman. Tokenization and stablecoins are transforming how assets are issued,...
Soleno Therapeutics to Participate in Upcoming November Conferences
Soleno Therapeutics to Participate in Upcoming November Conferences REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November: Guggenheim Securities Healthcare Innovation ConferencePresentation Date: Tuesday, November 11, 2025 at 9:00 AM ETPresentation Format: Fireside ChatWebcast: Stifel 2025 Healthcare ConferencePresentation Date: Wednesday, November 1...
Oxbridge Announces 2025 Third Quarter Results on November 6, 2025
Oxbridge Announces 2025 Third Quarter Results on November 6, 2025 GRAND CAYMAN, Cayman Islands, Oct. 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today reported its plans to hold a conference call on Thursday November 6, 2025 at 4:30 p.m. Eastern time to discuss results for the third quarter ending September 30, 2025. Financial results will be issued in a press release after the close of the market on the same day. Oxbridge’s management will host the conference...
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on ...
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Tuesday, November 4, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results an...
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn ...
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors Appointment adds three decades of financial and operational leadership to Soleno’s Board REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno’s Board n...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SCHL SCHOLASTIC CORPORATION
MRCY MERCURY SYSTEMS INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
KURA KURA ONCOLOGY INC.
JACK JACK IN THE BOX INC.
INTC INTEL CORPORATION
HELE HELEN OF TROY LIMITED
CROX CROCS INC.
AIR AAR CORP.
UNFI UNITED NATURAL FOODS INC.
LINK INTERLINK ELECTRONICS
SRRK SCHOLAR ROCK HOLDING CORPORATION
STOK STOKE THERAPEUTICS
IMTX IMMATICS N V (A)
KYMR KYMERA THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
COGT COGENT BIOSCIENCES INC
RLAY RELAY THERAPEUTICS
HIMS HIMS AND HERS HEALTH INC (A)
VERA VERA THERAPEUTICS INC
TNGX TANGO THERAPEUTICS INC
DSGN DESIGN THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
MBC_w MASTERBRAND INC
IRON DISC MEDICINE INC
CTNM CONTINEUM THERAPEUTICS INC
PACS PACS GROUP INC
ZBIO ZENAS BIOPHARMA INC.
UPB UPSTREAM BIO INC
MIR MIRION TECHNOLOGIES INC
SION SIONNA THERAPEUTICS INC
KLRS KALARIS THERAPEUTICS INC
BKTI BK TECHNOLOGIES CORP
EMPG EMPRO GROUP INC
Oxbridge / SurancePlus to Attend TOKEN2049 Singapore
Oxbridge / SurancePlus to Attend TOKEN2049 Singapore GRAND CAYMAN, Cayman Islands, Sept. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today announced it will participate in Singapore, taking place October 1–2, 2025 at the Marina Bay Sands. TOKEN2049 Singapore brings together industry leaders, innovators, and decision-makers from across the globe to connect, exchange ideas, and shape the future of digital assets and Web3. The event draws participants from more ...
Oxbridge / SurancePlus: 2025/26 Tokenized Reinsurance on Track for Tar...
Oxbridge / SurancePlus: 2025/26 Tokenized Reinsurance on Track for Targeted Returns GRAND CAYMAN, Cayman Islands, Sept. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today reported that its ZetaCat Re and EtaCat Re tokenized reinsurance securities for the 2025/2026 treaty year are on track to achieve their targeted returns of 20% and 42%, respectively. On June 1, 2025, launched its tokenized reinsurance securities offerings for the 2025/2026 treaty year, which ...
Design Therapeutics Appoints Justin Gover to Board of Directors
Design Therapeutics Appoints Justin Gover to Board of Directors CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company for over two decades, from inc...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PSTG PURE STORAGE INC. CLASS A
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
NTAP NETAPP INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
A AGILENT TECHNOLOGIES INC.
AGX ARGAN INC.
ELF E.L.F. BEAUTY INC.
CHCI COMSTOCK HOLDING COMPANIES
RCMT RCM TECHNOLOGIES
STNE STONECO
CSTL CASTLE BIOSCIENCES
SOFI SOFI TECHNOLOGIES INC
IMRX IMMUNEERING CORP
DSGN DESIGN THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
ASPI ASP ISOTOPES INC
FTREV FORTREA HOLDINGS INC.
KRRO KORRO BIO INC
RAPP RAPPORT THERAPEUTICS INC
ALMU AELUMA INC
RHLD RESOLUTE HOLDINGS MANAGEMENT INC
ASST ASSET ENTITIES INC
SNDK SANDISK CORP
INFU MULTI UNITS LU - AMUNDI US INFLATION EXPECTATIONS 10Y
Soleno Therapeutics to Participate in Upcoming September Conferences
Soleno Therapeutics to Participate in Upcoming September Conferences REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September: Cantor Global Healthcare ConferencePresentation Date: Wednesday, September 3, 2025 at 1:00 PM ETPresentation Format: Fireside ChatWebcast: Wells Fargo Healthcare ConferencePresentation Date: Thursday, September 4, 2025 at 1:30 ...
Design Therapeutics to Participate in the 2025 Cantor Global Healthcar...
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York. A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will be...
Oxbridge Highlights Growth in Tokenized Reinsurance, Strategic Partner...
Oxbridge Highlights Growth in Tokenized Reinsurance, Strategic Partnerships, and Reports Q2 2025 Results GRAND CAYMAN, Cayman Islands, Aug. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary , today reported its results for the quarter and six-month period ended June 30, 2025. “The quarter marked a pivotal moment for and . We have not only expanded our footprint in the rapidly growing tokenized reinsurance market but also forged strategic partnerships that position u...
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs ...
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 in FA Patients Underway Phase 2 Biomarker Study for DT-168 Initiated in Patients with Fuchs Endothelial Corneal Dystrophy (FECD) Cash and Securities of $216.3 Million Support Continued Pipeline Advancement CARLSBA...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.